Shiwani Randhawa

Shiwani Randhawa

Auto-generated profile, based on publicly available information

Shiwani Randhawa

Biotechnology Division, CSIR-Institute of Himalayan Bioresource Technology, Palampur, H.P. 176061, India; Academy of Scientific & Innovative Research (AcSIR), Ghaziabad 201002, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
Ashish Kumar ShuklaAshish Kumar Shukla
Ashish Kumar Shukla
SRShiwani Randhawa
Shiwani Randhawa
TSTrilok Chand Saini
Trilok Chand Saini
AAAmitabha Acharya
Amitabha Acharya

9 September 2023 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SASyed M.S. Abidi
Syed M.S. Abidi
CSChandni Sharma
Chandni Sharma
SRShiwani Randhawa
Shiwani Randhawa
Ashish Kumar ShuklaAshish Kumar Shukla
Ashish Kumar Shukla
AAAmitabha Acharya
Amitabha Acharya


22 April 2025 in Beilstein Journal of Nanotechnology
Verified
Journal Article
Open access
PDF file
SRShiwani Randhawa
Shiwani Randhawa
TSTrilok Chand Saini
Trilok Chand Saini
MBManik Bathla
Manik Bathla
RBRahul Bhardwaj
Rahul Bhardwaj
RDRubina Dhiman
Rubina Dhiman
AAAmitabha Acharya
Amitabha Acharya
The amyloid cascade hypothesis posits that amyloid-β oligomers (AβOs) are the most neurotoxic species in Alzheimer’s disease (AD). These oligomers, characterized by their high β-sheet content, have been shown to significantly disrupt cell membranes, induce local inflammation, and impair autophagy processes, which collectively contribute to neuronal loss. As such, targeting AβOs specifically, rather than solely focusing on amyloid-β fibrils (AβFs), may offer a more effective therapeutic approach for AD. Recent advances in detection and diagnosis have emphasized the importance of accurately identifying AβOs in patient samples, enhancing the potential for timely intervention. In recent years, nanomaterials (NMs) have emerged as promising agents for addressing AβOs regarding their multivalent interactions, which can more effectively detect and inhibit AβO formation. This review provides an in-depth analysis of various nanochaperones developed to target AβOs, detailing their mechanisms of action and therapeutic potential via focusing on two main strategies, namely, disruption of AβOs through direct interaction and the inhibition of AβO nucleation by binding to intermediates of the oligomerization process. Evidence from in vivo studies indicate that NMs hold promise for ameliorating AD symptoms. Additionally, the review explores the different interaction mechanisms through which nanoparticles exhibit their inhibitory effects on AβOs, providing insights into their potential for clinical application. This comprehensive overview highlights the current advancements in NM-based therapies for AD and outlines future research directions aimed at optimizing these innovative treatments.

24 March 2024 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
SASyed M.S. Abidi
Syed M.S. Abidi
Ashish Kumar ShuklaAshish Kumar Shukla
Ashish Kumar Shukla
SRShiwani Randhawa
Shiwani Randhawa
MBManik Bathla
Manik Bathla
AAAmitabha Acharya
Amitabha Acharya